Sanofi announces positive results for diabetes drug
PARIS (Reuters) - French drugmaker Sanofi said a late-stage study of its lixisenatide drug in combination with Lantus insulin showed a significant improvement in blood sugar levels and a beneficial effect on body weight in type 2 diabetes patients.
Lixisenatide, which will be sold under the Lyxumia brand name, belongs to the GLP-1 class of drugs that stimulate insulin release when glucose levels become too high.
It is seen as a possible blockbuster that could help Sanofi become the world's top diabetes treatment company.
"These positive results show that once-daily lixisenatide in combination with Lantus could be an innovative therapeutic option for the treatment of uncontrolled type 2 diabetes," Pierre Chancel, senior vice-president of Sanofi Diabetes, said in a statement on Tuesday.
European authorities accepted Sanofi's marketing application for Lyxumia last month, while the company plans to file a request for regulatory approval for the drug in the United States in the fourth quarter of next year, Sanofi said.
- British Muslim calls for action on jihadi subculture after beheading video |
- Obama condemns killing of reporter, U.S. hits militants in Iraq |
- Israeli air strike kills three Hamas commanders in Gaza |
- Stocks extend rally, S&P hits new high as data signals growth
- Thai junta leader appointed PM by hand-picked parliament |
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video